APRE Stock — Aprea Therapeutics Inc

Aprea Therapeutics Inc (APRE)

APRE is a low-cost Stock. Total return is -99.8% over the past 6.9 years, 294.5 points behind SPY at 194.7%.

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing novel cancer therapies that target DNA damage response pathways, with lead candidates APR-1051 (a WEE1 kinase inhibitor) and ATRN-119 (an ATR inhibitor) currently in Phase 1 and Phase 1/2a clinical trials for solid tumors. The company does not currently distribute dividends. Aprea appeals to investors with high risk tolerance who seek exposure to early-stage cancer drug development.

APRE performance versus SPY

Data as of August 17, 2026.

Total return is -99.8% over the past 6.9 years, 294.5 points behind SPY at 194.7%. Its deepest 1-year drawdown was 65.1%.

APRE key facts

Data as of August 17, 2026.

Asset type

Stock

Asset class

Equity

Inception date

10/03/2019

Last close

$0.68

Market cap

$8,785,580

Average volume

15800.0

Beta

1.564

Payout ratio

0.0

Forward P/E

0.0

EPS

$-1.49

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. We show a 30-day SEC yield when the fund publishes one. Schwab and other issuers may report a TTM distribution yield or SEC yield on a different date — all can be valid; they are not interchangeable. Total return uses split-adjusted close with distributions reinvested from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. Figures below use Dividend Vision data as of August 17, 2026.

Distribution rate methodology · Distribution Safety Score methodology · SEC yield

Sources and review

Data as of August 17, 2026.

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

APRE risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 65.1%.

Who may consider APRE — and who may not

APRE may suit someone looking for low-cost broad dividend exposure. It is a weaker fit for investors hunting double-digit covered-call yields; investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

Frequently asked questions